Cellular RNAs are known to be invariably bound to and often modified by RNA-binding proteins (RBPs). Accordingly, RBPs play key roles in regulating many aspects of coding and non-coding RNA biology, including RNA processing, nuclear export, cellular transport, function, localization, and stability. Disruption of the complex network of RNA-protein interactions (RPIs) has been implicated in a number of human diseases including neurodegenerative, neuromuscular, neurodevelopmental and cardiovascular diseases, encephalo-, ribosomo- and neuropathies, autoimmune disorders, and many types of cancer. Thus, the targeting of RBPs and RPIs has arisen as a new frontier in RNA-targeted drug discovery. In this talk, I will discuss our laboratory’s efforts towards the development and application of innovative assay technologies, as well as rational medicinal chemistry approaches, for targeting RPIs to enable the discovery of novel RNA-targeted therapeutics.

David W. Robertson award: Expanding opportunities for targeting RNA-binding proteins

Fall 2022 abstracts, posters, and presentations will launch in mid-September.

ACS Fall 2022

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.